Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Exp Neurol. 2020 Jan 31;327:113219. doi: 10.1016/j.expneurol.2020.113219

Figure 6. Altered expression of enzymes involved in NAD+ synthesis in the spinal cord of ALS patients.

Figure 6.

A–F) Total RNA was extracted from spinal cord tissue of non-ALS controls (controls) and ALS patients. mRNA levels for NAMPT, NMNAT1, NMNAT2, NMNAT3, NAPRT and NMRK1 were determined by real-time PCR and corrected by TBP mRNA levels. For all panels, data are expressed as percentage of controls (mean ± SD, n=15 in each group). G) NMNAT2 immunostaining in the ventral horn of the spinal cord from three different non-ALS controls (control) and three different ALS patients. Each set corresponds to a different control and ALS tissue sections mounted on the same slide. All sections were stained and developed concurrently. Scale bar: 100μm. H) NMNAT2 protein levels in the spinal cord tissue of non-ALS controls (control) and ALS patients. ACTIN levels were used as loading control for normalization. I) Quantification of NMNAT2 levels shown in (H) (mean ± SD, n=6 in each group).